Research graph
References from Simultaneous Inhibition of PARP-1 and CK2α by Novel Benzothieno[3,2- <i>d</i> ]pyrimidin-4(1 <i>H</i> )-one Derivatives: A Promising Strategy to Combat Homologous Recombination Deficiency-Independent Tumors and Metastasis. Local targets link to admitted publications; unresolved targets remain external evidence.
Abstract 2854: The role of NONO in genome stability: Implications for RNA-DNA hybrid accumulation, genomic instability, and inflammatory signaling
10.1158/1538-7445.am2025-2854 · 2025 · External reference
Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1 inhibitors
10.1186/s13065-025-01389-2 · 2025 · External reference
Synthetic lethal strategies for the development of cancer therapeutics
10.1038/s41571-024-00966-z · 2025 · External reference
Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment
10.3892/ijo.2023.5476 · 2023 · External reference
Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective
10.1186/s40364-026-00908-0 · 2026 · External reference
Discovery of a dual tubulin and poly(ADP-ribose) polymerase-1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular docking, and biological evaluation
10.1021/acs.jmedchem.1c00932 · 2021 · External reference
Advancements in nanotechnology for PARP inhibitor delivery: a comprehensive review of diverse nanosystems, their mechanisms, and therapeutic applications across cancer and beyond
10.1080/09205063.2025.2534698 · 2026 · External reference
In vitro analysis of PARP inhibitor nanoformulations
10.2147/ijn.s124992 · 2018 · External reference
Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials
10.1016/j.critrevonc.2020.103145 · 2021 · External reference
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities
10.1016/j.ygyno.2018.01.011 · 2018 · External reference
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness
10.1593/neo.131694 · 2014 · External reference
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
10.1016/j.tranon.2021.101012 · 2021 · External reference
Inhibiting CK2 in breast cancer: From molecular targets to drug candidates
10.1016/j.ejmech.2026.118620 · 2026 · External reference
Discovery of 5-(3-chlorophenylamino)benzo[c] [2,6]naphthyridine derivatives as highly selective CK2 inhibitors with potent cancer cell stemness inhibition
10.1021/acs.jmedchem.1c00131 · 2021 · External reference
A comprehensive review on the dynamics of protein kinase CK2 in cancer development and optimizing therapeutic strategies
10.1016/j.ijbiomac.2024.135814 · 2024 · External reference
Regulation of cancer progression by CK2: an emerging therapeutic target
10.1007/s12032-024-02316-6 · 2024 · External reference
XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair
10.1016/j.dnarep.2010.04.008 · 2010 · External reference
CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response
10.1093/nar/gkp1149 · 2010 · External reference
Novel CK2-specific Pt(II) compound reverses cisplatin-induced resistance by inhibiting cancer cell stemness and suppressing DNA damage repair in non-small cell lung cancer treatments
10.1021/acs.jmedchem.1c00079 · 2021 · External reference
CK2α causes stemness and chemotherapy resistance in liver cancer through the Hedgehog signaling pathway
10.1016/j.hbpd.2021.09.003 · 2023 · External reference
an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington’s disease mouse model
10.1016/j.neurot.2026.e00859 · 2026 · External reference
Abstract CT271: Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors
10.1158/1538-7445.am2026-ct271 · 2026 · External reference
PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications
10.1016/j.tranon.2026.102757 · 2026 · External reference
PS4-05-30: Maged1 inhibition enhances sensitivity to parp inhibitors in brca-mutated breast cancer cells
10.1158/1557-3265.sabcs25-ps4-05-30 · 2026 · External reference
CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites
10.1038/s41467-019-10735-7 · 2019 · External reference
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
10.1186/s12943-020-01167-9 · 2020 · External reference
Prevalence and prognosis of BRCAm, homologous recombination repair mutation (HRRm) or HR deficiency positive (HRD+) across tumor types
10.1200/jco.2022.40.16_suppl.e18802 · 2022 · External reference
Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin
10.1093/nar/gkw1246 · 2017 · External reference
Artificial intelligence in drug discovery and development: transforming pharmaceutical innovation
10.1002/ddr.70281 · 2026 · External reference
Artificial intelligence in drug discovery: Integrative advances from data to therapeutic innovation
10.1002/ddr.70229 · 2026 · External reference
Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d] pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors
10.1016/j.bioorg.2023.106759 · 2023 · External reference
Discovery of novel bromophenol−thiosemicarbazone hybrids as potent selective inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for use in cancer
10.1021/acs.jmedchem.8b01946 · 2019 · External reference
PARP1 inhibitors: antitumor drug design
10.32607/20758251-2015-7-3-27-37 · 2015 · External reference
Impaired PARP1-dependent DNA repair in MORC2 mutations drives axonal degeneration in Charcot-Marie-Tooth disease subtype 2Z and spinal muscular atrophy-like neuromotor disorders
10.1016/j.phrs.2026.108103 · 2026 · External reference
Superenhancers shape the landscape and repair dynamics of transcription-associated DNA breaks in cancer
10.1126/sciadv.aeb6379 · 2026 · External reference
Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV1.5-mediated EMT and FAK/Paxillin signaling pathway
10.1002/cam4.3621 · 2021 · External reference
PARP1 bound to XRCC2 promotes tumor progression in colorectal cancer
10.1007/s12672-024-01112-y · 2024 · External reference
Phosphorylation-dependent stabilization of MZF1 upregulates N-cadherin expression during protein kinase CK2-mediated epithelial-mesenchymal transition
10.1038/s41389-018-0035-9 · 2018 · External reference
The WT1 protein molecule drives the proliferation and metastasis of anaplastic thyroid carcinoma through the EMT process
10.1016/j.ijbiomac.2025.148170 · 2025 · External reference
CK2α deletion in the hematopoietic compartment shows a mild alteration in terminally differentiated cells and the expansion of stem cells
10.3390/cells14130963 · 2025 · External reference
S-palmitoylation of c-MET by CK2α-mediated zDHHC15 phosphorylation drives glioblastoma stem cell tumorigenicity
10.1093/neuonc/noaf098 · 2025 · External reference
Characterization of SOX2, OCT4 and NANOG in ovarian cancer tumor-initiating cells
10.3390/cancers13020262 · 2021 · External reference
DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1
10.1038/s41419-018-0585-y · 2018 · External reference
Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV1.5-mediated EMT and FAK/Paxillin signaling pathway
10.1002/cam4.3621 · ExternalCitation · doi-reference
Artificial intelligence in drug discovery: Integrative advances from data to therapeutic innovation
10.1002/ddr.70229 · ExternalCitation · doi-reference
Artificial intelligence in drug discovery and development: transforming pharmaceutical innovation
10.1002/ddr.70281 · ExternalCitation · doi-reference
Regulation of cancer progression by CK2: an emerging therapeutic target
10.1007/s12032-024-02316-6 · ExternalCitation · doi-reference
PARP1 bound to XRCC2 promotes tumor progression in colorectal cancer
10.1007/s12672-024-01112-y · ExternalCitation · doi-reference
Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d] pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors
10.1016/j.bioorg.2023.106759 · ExternalCitation · doi-reference
Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials
10.1016/j.critrevonc.2020.103145 · ExternalCitation · doi-reference
XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair
10.1016/j.dnarep.2010.04.008 · ExternalCitation · doi-reference
Inhibiting CK2 in breast cancer: From molecular targets to drug candidates
10.1016/j.ejmech.2026.118620 · ExternalCitation · doi-reference
CK2α causes stemness and chemotherapy resistance in liver cancer through the Hedgehog signaling pathway
10.1016/j.hbpd.2021.09.003 · ExternalCitation · doi-reference
A comprehensive review on the dynamics of protein kinase CK2 in cancer development and optimizing therapeutic strategies
10.1016/j.ijbiomac.2024.135814 · ExternalCitation · doi-reference
The WT1 protein molecule drives the proliferation and metastasis of anaplastic thyroid carcinoma through the EMT process
10.1016/j.ijbiomac.2025.148170 · ExternalCitation · doi-reference
an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington’s disease mouse model
10.1016/j.neurot.2026.e00859 · ExternalCitation · doi-reference
Impaired PARP1-dependent DNA repair in MORC2 mutations drives axonal degeneration in Charcot-Marie-Tooth disease subtype 2Z and spinal muscular atrophy-like neuromotor disorders
10.1016/j.phrs.2026.108103 · ExternalCitation · doi-reference
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
10.1016/j.tranon.2021.101012 · ExternalCitation · doi-reference
PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications
10.1016/j.tranon.2026.102757 · ExternalCitation · doi-reference
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities
10.1016/j.ygyno.2018.01.011 · ExternalCitation · doi-reference
Novel CK2-specific Pt(II) compound reverses cisplatin-induced resistance by inhibiting cancer cell stemness and suppressing DNA damage repair in non-small cell lung cancer treatments
10.1021/acs.jmedchem.1c00079 · ExternalCitation · doi-reference
Discovery of 5-(3-chlorophenylamino)benzo[c] [2,6]naphthyridine derivatives as highly selective CK2 inhibitors with potent cancer cell stemness inhibition
10.1021/acs.jmedchem.1c00131 · ExternalCitation · doi-reference
Discovery of a dual tubulin and poly(ADP-ribose) polymerase-1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular docking, and biological evaluation
10.1021/acs.jmedchem.1c00932 · ExternalCitation · doi-reference
Discovery of novel bromophenol−thiosemicarbazone hybrids as potent selective inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for use in cancer
10.1021/acs.jmedchem.8b01946 · ExternalCitation · doi-reference
Phosphorylation-dependent stabilization of MZF1 upregulates N-cadherin expression during protein kinase CK2-mediated epithelial-mesenchymal transition
10.1038/s41389-018-0035-9 · ExternalCitation · doi-reference
DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1
10.1038/s41419-018-0585-y · ExternalCitation · doi-reference
CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites
10.1038/s41467-019-10735-7 · ExternalCitation · doi-reference
Synthetic lethal strategies for the development of cancer therapeutics
10.1038/s41571-024-00966-z · ExternalCitation · doi-reference
Advancements in nanotechnology for PARP inhibitor delivery: a comprehensive review of diverse nanosystems, their mechanisms, and therapeutic applications across cancer and beyond
10.1080/09205063.2025.2534698 · ExternalCitation · doi-reference
CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response
10.1093/nar/gkp1149 · ExternalCitation · doi-reference
Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin
10.1093/nar/gkw1246 · ExternalCitation · doi-reference
S-palmitoylation of c-MET by CK2α-mediated zDHHC15 phosphorylation drives glioblastoma stem cell tumorigenicity
10.1093/neuonc/noaf098 · ExternalCitation · doi-reference
Superenhancers shape the landscape and repair dynamics of transcription-associated DNA breaks in cancer
10.1126/sciadv.aeb6379 · ExternalCitation · doi-reference
Abstract 2854: The role of NONO in genome stability: Implications for RNA-DNA hybrid accumulation, genomic instability, and inflammatory signaling
10.1158/1538-7445.am2025-2854 · ExternalCitation · doi-reference
Abstract CT271: Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors
10.1158/1538-7445.am2026-ct271 · ExternalCitation · doi-reference
PS4-05-30: Maged1 inhibition enhances sensitivity to parp inhibitors in brca-mutated breast cancer cells
10.1158/1557-3265.sabcs25-ps4-05-30 · ExternalCitation · doi-reference
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
10.1186/s12943-020-01167-9 · ExternalCitation · doi-reference
Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1 inhibitors
10.1186/s13065-025-01389-2 · ExternalCitation · doi-reference
Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective
10.1186/s40364-026-00908-0 · ExternalCitation · doi-reference
Prevalence and prognosis of BRCAm, homologous recombination repair mutation (HRRm) or HR deficiency positive (HRD+) across tumor types
10.1200/jco.2022.40.16_suppl.e18802 · ExternalCitation · doi-reference
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness
10.1593/neo.131694 · ExternalCitation · doi-reference
In vitro analysis of PARP inhibitor nanoformulations
10.2147/ijn.s124992 · ExternalCitation · doi-reference
PARP1 inhibitors: antitumor drug design
10.32607/20758251-2015-7-3-27-37 · ExternalCitation · doi-reference
Characterization of SOX2, OCT4 and NANOG in ovarian cancer tumor-initiating cells
10.3390/cancers13020262 · ExternalCitation · doi-reference
CK2α deletion in the hematopoietic compartment shows a mild alteration in terminally differentiated cells and the expansion of stem cells
10.3390/cells14130963 · ExternalCitation · doi-reference
Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment
10.3892/ijo.2023.5476 · ExternalCitation · doi-reference
